Pulmonary Immune Cell-microbiome Interactions in the Healthy Lung
Pulmonary Immune Cell-microbiome Interactions in the Healthy Lung: the ILLUMINA-2 Study
Hvidovre University Hospital
50 participants
Apr 17, 2023
OBSERVATIONAL
Conditions
Summary
The overall aim is to to provide a normal material for the composition and spatial heterogeneity of the following in the healthy lung: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome. Main hypotheses: * Absolute and relative immune cell counts in bronchoalveolar lavage fluid (BALF) are similar to those previously reported by other methods6,7. * No trans-compartmental flux of cytokines between the lungs and bloodstream is present, but cytokine concentrations (notably IL-6 and IL-8) vary with the immune-cell-microbiome composition. * Immune cell (mainly T cell) activation, differentiation, and gene expression patterns are expected to differ between blood and BALF in a manner that depends on the regional diversity of the pulmonary microbiome.
Eligibility
Inclusion Criteria2
- Men and women
- Age 40 to 75
Exclusion Criteria8
- Immune deficiency
- Lung disease
- Active cancer or infection
- Absolute contraindications for bronchoscopy
- Untreated malignant arrhythmia
- Documented or suspected intracranial hypertension (intracranial pressure ≥ > 15 mmHg)
- One-lung ventilation
- Severe coagulopathy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05846620